Success Metrics

Clinical Success Rate
85.7%

Based on 84 completed trials

Completion Rate
86%(84/98)
Active Trials
7(5%)
Results Posted
62%(52 trials)
Terminated
14(10%)

Phase Distribution

Ph phase_4
25
18%
Ph early_phase_1
2
1%
Ph phase_2
45
32%
Ph phase_3
16
11%
Ph not_applicable
15
11%
Ph phase_1
36
26%

Phase Distribution

38

Early Stage

45

Mid Stage

41

Late Stage

Phase Distribution139 total trials
Early Phase 1First-in-human
2(1.4%)
Phase 1Safety & dosage
36(25.9%)
Phase 2Efficacy & side effects
45(32.4%)
Phase 3Large-scale testing
16(11.5%)
Phase 4Post-market surveillance
25(18.0%)
N/ANon-phased studies
15(10.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.6%

84 of 103 finished

Non-Completion Rate

18.4%

19 ended early

Currently Active

7

trials recruiting

Total Trials

140

all time

Status Distribution
Active(12)
Completed(84)
Terminated(19)
Other(25)

Detailed Status

Completed84
unknown23
Terminated14
Recruiting5
Withdrawn5
Not yet recruiting4

Development Timeline

Analytics

Development Status

Total Trials
140
Active
7
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (1.4%)
Phase 136 (25.9%)
Phase 245 (32.4%)
Phase 316 (11.5%)
Phase 425 (18.0%)
N/A15 (10.8%)

Trials by Status

active_not_recruiting21%
completed8460%
enrolling_by_invitation11%
not_yet_recruiting43%
recruiting54%
terminated1410%
withdrawn54%
suspended21%
unknown2316%

Recent Activity

Clinical Trials (140)

Showing 20 of 140 trialsScroll for more
NCT06699966Phase 4

Stony Brook Medicine Anti-Inflammatory Trial

Not Yet Recruiting
NCT06120140Phase 2

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Recruiting
NCT03947827Phase 3

Minocycline as Adjunctive Treatment for Treatment Resistant Depression

Completed
NCT05902819Not Applicable

Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories

Completed
NCT03489629Phase 2

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

Completed
NCT07305896Not Applicable

Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage

Not Yet Recruiting
NCT06107725Phase 2

Maimonides Minocycline in Stroke Study

Terminated
NCT02564978Phase 2

Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration

Completed
NCT06201793Phase 2

Minocyclin in Ulcerative Colitis as Added on Therapy

Completed
NCT07068607Phase 4

Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial

Recruiting
NCT06033846Phase 2

Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis

Completed
NCT03414502Phase 3

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting
NCT05487417Phase 4

Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy

Recruiting
NCT02113176Phase 1

Minocycline as Neuroprotectant After Aneurysmal Subarachnoid Hemorrhage

Withdrawn
NCT06523764Phase 4

Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment

Active Not Recruiting
NCT02213575Phase 2

Study 3: Minocycline Decreases Microglia Activation

Completed
NCT05861258Phase 2

Pharmacokinetic Study of Minocycline in Patients With Pulmonary Nontuberculous Mycobacterial Disease

Terminated
NCT05512910Phase 4

Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B)

Active Not Recruiting
NCT02719392Phase 4

A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression

Suspended
NCT02515955Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants

Completed

Drug Details

Intervention Type
DRUG
Total Trials
140